What is the Selective Serotonin Reuptake Inhibitor (SSRI) with the least sexual side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

SSRI with the Least Sexual Side Effects

Among SSRIs, escitalopram and fluvoxamine cause the lowest rates of sexual dysfunction, though bupropion (not an SSRI) has significantly lower sexual side effects than any SSRI and should be considered first-line when sexual function is a major concern. 1

Evidence-Based Ranking of SSRIs by Sexual Dysfunction Risk

Lowest Risk SSRIs

  • Escitalopram and fluvoxamine demonstrate the lowest rates of sexual dysfunction among all SSRIs, though specific incidence rates are not well-quantified in guidelines 1
  • Sertraline causes sexual dysfunction in approximately 14% of males (ejaculatory failure) and 6% decreased libido in combined male/female populations, placing it in the moderate range 1, 2
  • Citalopram has intermediate rates of sexual dysfunction, though it is preferred over paroxetine or fluoxetine when an SSRI must be used 1

Highest Risk SSRIs

  • Paroxetine has the highest rates of sexual dysfunction among all SSRIs at 70.7%, with significantly higher rates than fluoxetine, fluvoxamine, nefazodone, or sertraline 3, 1, 4
  • Fluoxetine has intermediate to higher rates of sexual dysfunction compared to other SSRIs 1

Critical Clinical Considerations

Non-SSRI Alternative

  • Bupropion has significantly lower sexual dysfunction rates (8-10%) compared to all SSRIs and should be considered first-line when sexual function is a major concern 3, 1
  • Bupropion showed significantly lower rates of sexual adverse events than fluoxetine or sertraline in head-to-head comparisons 3
  • Bupropion should not be used in agitated patients or those with seizure disorders due to increased seizure risk 3

Newer Antidepressants

  • Vortioxetine shows low rates of sexual dysfunction and demonstrated significantly greater improvements in sexual function compared to escitalopram when switching from SSRIs causing sexual dysfunction 5, 6, 7
  • Vortioxetine's multimodal mechanism (5-HT3, 5-HT7 antagonism plus SERT inhibition) may account for its lower sexual side effect profile 7
  • Vilazodone (SSRI plus 5-HT1A partial agonist) has reduced sexual side effects compared to traditional SSRIs due to its dual mechanism 8

Important Caveats

Underreporting of Sexual Dysfunction

  • Sexual dysfunction rates are vastly underreported in clinical trials, with actual rates likely higher than published figures 1
  • Absolute rates of sexual dysfunction are probably underreported because patients and physicians may be reluctant to discuss them 2
  • Physicians should routinely inquire about sexual function before and during SSRI treatment, as patients may not spontaneously report these symptoms 5, 2

Dose-Related Effects

  • Sexual side effects of SSRIs are strongly dose-related, so reducing to the minimum effective dose may help 4
  • Most sexual adverse effects emerge within the first few weeks of treatment 3

Management Strategy When Sexual Dysfunction Occurs

  • Switching to bupropion is recommended as first-line therapy when sexual dysfunction occurs with an SSRI 1
  • Bupropion-sustained release at doses of 100-200 mg/day showed improvement in SSRI-induced sexual side effects within the first 2 weeks, with global response rates of 75% in men and 46% in women 9
  • Switching to vortioxetine may be beneficial for patients experiencing sexual dysfunction during SSRI therapy 6

References

Guideline

SSRI-Associated Sexual Dysfunction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of SSRI-Induced Sexual Dysfunction in Men

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.